• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·HIMS
Held by 3 Gurus
Share

Hims & Hers Health, Inc. Stocks

$ 28.78Last Updated 28.09.2026

Issuer Rating

2/7
Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

$ 6.56B

$ 28.78
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

In Guru Portfolios

Steven Cohen

Portfolio Weight (%)

0.1%

Change

+0.06%

Fund

Point72 Asset Management, L.P.

Kenneth Griffin

Portfolio Weight (%)

0.0%

Change

+0.00%

Fund

CITADEL ADVISORS LLC

Bob Prince, Greg Jensen, Karen Karniol-Tambour

Portfolio Weight (%)

0.0%

Change

-0.00%

Fund

Bridgewater Associates

Manager
Fund
Portfolio Weight (%)
Change
Steven CohenPoint72 Asset Management, L.P.0.1%+0.06%
Kenneth GriffinCITADEL ADVISORS LLC0.0%+0.00%
Bob Prince, Greg Jensen, Karen Karniol-TambourBridgewater Associates0.0%-0.00%

Latest news

11.08.2026 15:27

Morning in New York: Stock Indices Near All-Time Highs

27.03.2026 14:48

The obesity therapy market is changing. What smid-cap investors should know.

10.03.2026 15:34

Morning in New York: quotes remain in the turbulence zone

09.03.2026 19:09

Shares of online pharmacy Hims & Hers soared 40% amid a general sell-off. What is it?

23.02.2026 16:24

Hims & Hers to buy Australian peer Eucalyptus amid GLP-1 regulatory, legal pressure

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Hims & Hers Health, Inc. operates a comprehensive digital health platform that seamlessly links individuals with licensed medical professionals for virtual consultations and ongoing care. Through its user-friendly websites and mobile app, the company delivers a diverse portfolio of health and wellness solutions directly to consumers. This includes access to recurring prescription medications, alongside a wide selection of over-the-counter drugs, devices, cosmetics, and dietary supplements. Its core focus areas are general wellness, sexual health, skincare, and hair care. Specific non-prescription offerings span categories such as: Wellness: encompassing items like vitamin C, melatonin, biotin, and collagen protein supplements. Skincare: including products such as moisturizers, serums, and face washes. Sexual Health: providing essentials like condoms, climax delay sprays and wipes, vibrators, and lubricants. Hair Care: offering specialized shampoos, conditioners, scalp scrubs, and topical treatments like minoxidil. Beyond direct sales, Hims & Hers also distributes health and wellness products via wholesale partnerships. The company's headquarters are located in San Francisco, California.

Company Valuation

Overvalued
2/7

From both historical and forecast perspectives, the stock is overpriced compared to similar stocks. In particular, the stock is 'expensive' on EV/EBITDA, trading at neutr

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of HIMS is 29.6 and suggests 2.39% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendatio

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

29.09.2026 16:15

The Crisis in the Strait of Hormuz and Routes to China: How to Invest in a Changing Transportation Market

29.09.2026 16:00

Morning in New York: Stocks Remain Volatile

29.09.2026 15:40

Burry increased his stake in the mid-cap retailer Sprouts. Should you follow his lead?

29.09.2026 15:20

The maker of Zuckerberg's "favorite" smart rings has postponed its IPO due to "uncertainty"

29.09.2026 14:39

Morgan Stanley has identified 12 stocks with growth potential of 40% or more amid an AI computing capacity shortage

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026